

## Affinium Pharmaceuticals

[View the current Affinium Pharmaceuticals Page on BioPortfolio.com](http://www.bioportfolio.com/biorporate/225-Affinium+Pharmaceuticals.html)

(<http://www.bioportfolio.com/biorporate/225-Affinium+Pharmaceuticals.html>)

### Contact Details:

1243 Islington Ave., Suite 600

Toronto

Ontario

M8X 1Y9

Canada

Tel: 416-645-6613

Fax: 416-646-1553

Email: [oroberts@afnm.com](mailto:oroberts@afnm.com)

Affinium Pharmaceuticals is a specialty pharmaceutical company focused on the discovery, development and commercialization of novel anti-infective medicines. AFN-1252 utilizes a unique mechanism of action by directly inhibiting the function of the bacterial fatty acid synthesis (FAS) II pathway. Affinium's FASII antibacterial programs constitute a new antibiotic franchise with the potential for multiple products targeting the FASII pathway. These programs include a broad base of long-term intellectual property: issued and pending composition of matter patents on potent orally available small molecule inhibitors of a new class of antibiotics with a unique mechanism of action, targeting an underexploited pathway and are not subject to resistance selection pressures caused by the use of existing broad spectrum antibiotics.

### Recent Publications by Affinium Pharmaceuticals:



- [Expression profiling of herpesvirus and vaccinia virus proteins using a high-throughput baculovirus screening system.](#)

*We have developed a high-throughput system for generating baculoviruses...*9th February, 2006  
Affinium Pharmaceuticals, Toronto, Canada.- J Proteome Res. 2005 Nov-Dec;4(6):2225-35. ([DOI Direct Link](#))

- [The structure of \(3R\)-hydroxyacyl-acyl carrier protein dehydratase \(FabZ\) from Pseudomonas aeruginosa.](#)

*Type II fatty acid biosynthesis systems are essential for membrane...*3rd February, 2005  
Affinium Pharmaceuticals, Toronto, Ontario M5J 1V6, Canada.- J Biol Chem. 2004 Dec 10;279(50):52593-602. Epub 2004 Sep 14. ([DOI Direct Link](#))

- [Reduced triclosan susceptibility in methicillin-resistant Staphylococcus epidermidis.](#)

*Triclosan MIC determination showed that recent Staphylococcus aureus...*25th May, 2004  
Affinium Pharmaceuticals, Inc., Toronto, Ontario M5J 1V6, Canada.- Antimicrob Agents Chemother.

2004 Apr;48(4):1397-9.

- [High-throughput protein crystallization.](#)

*High-throughput structural biology is a focus of a number of academic and...* 10th February, 2004  
Affinium Pharmaceuticals, 100 University Avenue, Ont., Toronto, Canada.- J Struct Biol. 2003  
Apr;142(1):154-61.

- [Data mining crystallization databases: knowledge-based approaches to optimize protein crystal screens.](#)

*Protein crystallization is a major bottleneck in protein X-ray...* 23rd July, 2003  
Affinium Pharmaceuticals Inc., Toronto, Ontario, Canada.- Proteins. 2003 Jun 1;51(4):562-8. ([DOI](#)  
[Direct Link](#))

- [Structural proteomics: the potential of high-throughput structure determination.](#)

*The pharmaceutical industry has embraced genomics as a means to identify...* 26th November, 2002  
Affinium Pharmaceuticals, 100 University Avenue, Toronto, Ontario, Canada.- Trends Microbiol.  
2002;10(10 Suppl):S27-31.

## BioNews Results for Affinium Pharmaceuticals



- [Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Globa](#)

*SmartBrief: Sep 1 2008 12:22AM Matching: pharmaceuticals*

- [Barr Receives Approval for Generic Version of Razadyne\(R\) Tablets](#)

*Montana's News Station: Aug 31 2008 2:04PM Matching: pharmaceuticals*

- [Barr Receives Approval for Generic Version of Razadyne\(R\) Tablets](#)

*KSLA: Aug 30 2008 3:44PM Matching: pharmaceuticals*

- [Barr Receives Approval for Generic Version of Razadyne\(R\) Tablets](#)

*KRON4: Aug 30 2008 11:18AM Matching: pharmaceuticals*

- [Is Bigger Really Better?](#)

*Signals Magazine: Aug 29 2008 3:44AM Matching: pharmaceuticals*

- [Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conf](#)

*KOTA Territory News: Aug 29 2008 5:04PM Matching: pharmaceuticals*

- [Cadence Pharmaceuticals Appoints Todd Rich, M.D. to its Board of Directors and Names Malcolm Lloyd-Smith as Se](#)

*Business Journal of Milwaukee: Aug 28 2008 10:05PM Matching: pharmaceuticals*

- [Cadence Pharmaceuticals Appoints Todd Rich, M.D. to its Board of Directors and Names Malcolm Lloyd-Smith as Se](#)

*San Antonio Business Journal: Aug 28 2008 10:05PM Matching: pharmaceuticals*

- [Cadence Pharmaceuticals Appoints Todd Rich, M.D. to its Board of Directors and Names Malcolm Lloyd-Smith as Se](#)

*Columbus Business First: Aug 28 2008 9:58PM Matching: pharmaceuticals*

- [Cadence Pharmaceuticals Appoints Todd Rich, M.D. to its Board of Directors and Names Malcolm Lloyd-Smith as Se](#)

*San Francisco Business Times: Aug 28 2008 9:55PM Matching: pharmaceuticals*

- [Cadence Pharmaceuticals Appoints Todd Rich, M.D. to its Board of Directors and Names Malcolm Lloyd-Smith as Se](#)

*Cincinnati Business Journal: Aug 28 2008 9:44PM Matching: pharmaceuticals*

- [Cadence Pharmaceuticals Appoints Todd Rich, M.D. to its Board of Directors and Names Malcolm](#)

### [Lloyd-Smith as Se](#)

*The Business Journal Phoenix: Aug 28 2008 9:43PM Matching: pharmaceuticals*

- [Cadence Pharmaceuticals Appoints Todd Rich, M.D. to its Board of Directors and Names Malcolm Lloyd-Smith as Se](#)

*Nashville Business Journal: Aug 28 2008 9:39PM Matching: pharmaceuticals*

- [Cadence Pharmaceuticals Appoints Todd Rich, M.D. to its Board of Directors and Names Malcolm Lloyd-Smith as Se](#)

*Atlanta Business Chronicle: Aug 28 2008 9:39PM Matching: pharmaceuticals*

- [Cadence Pharmaceuticals Appoints Todd Rich, M.D. to its Board of Directors and Names Malcolm Lloyd-Smith as Se](#)

*Atlanta Business Chronicle: Aug 28 2008 9:39PM Matching: pharmaceuticals*

### **Affinium Pharmaceuticals Patents:**



- 7250424- [Fab I inhibitors](#)
- 6673941- [Disubstituted imidazoles useful in the treatment of bacterial infections](#)
- 6730684- [Fab I inhibitors](#)
- 6753172- [FabI](#)
- 6762201- [Fab I inhibitors](#)
- 6765005- [Fab I inhibitors](#)
- 6797523- [Methods for systematic identification of protein--protein interactions](#)
- 6821746- [Methods of screening for FabK antagonists and agonists](#)
- 6846819- [Fab I inhibitors](#)
- 6951729- [High throughput screening method for biological agents affecting fatty acid biosynthesis](#)
- 6964970- [Antibacterial compounds](#)
- 6995254- [Polynucleotide encoding the enoyl-acyl carrier protein reductase of Staphylococcus aureus, FAB I](#)
- 7033795- [FabK variant](#)
- 7048926- [Methods of agonizing and antagonizing FabK](#)
- 7049310- [Fab I inhibitors](#)
- 7056697- [FabK variant](#)
- 7176299- [Compounds](#)
- 7250285- [Purified polypeptides from Streptococcus pneumoniae](#)
- 6573272- [Antibacterial compounds](#)

## **BioCorporate Profiles - upgrade to a full profile**

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's relate service indepth.

The annual cost is \$495.00 for established organizations and \$295.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

